Suspended PHASE2 INTERVENTIONAL 1-arm NCT05089461

A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor

An Open-label, Multi-center Phase II Clinical Trial to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor

Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Conditions Advanced Malignant Tumor

Interventions Mitoxantrone Hydrochloride Liposome

Updated 4 times since 2021 Last updated: Sep 7, 2022 Started: Mar 7, 2022 Primary completion: Jun 20, 2022 Completion: Dec 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Suspended

sponsor decided to stop

This PHASE2 trial investigates Advanced Malignant Tumor and is currently suspended. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. leads this study, which shows 4 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Suspended PHASE2
Jul 2024 — Sep 2024 [monthly]

Suspended PHASE2
Sep 2022 — Jul 2024 [monthly]

Suspended PHASE2

Status: Not Yet Recruiting → Suspended
Nov 2021 — Sep 2022 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Data source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dalian, China